Detalles de la búsqueda
1.
Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial.
Clin Gastroenterol Hepatol
; 21(7): 1893-1901.e7, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842120
2.
Genome-wide meta-analysis identifies susceptibility loci for autoimmune hepatitis type 1.
Hepatology
; 76(3): 564-575, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35184318
3.
Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.
BMC Gastroenterol
; 23(1): 224, 2023 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37386460
4.
IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation.
Dig Dis
; 41(6): 922-931, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37586356
5.
On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.
Liver Int
; 38(6): 1045-1054, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29119705
6.
Transient Elastography with Serum Hepatitis B Surface Antigen Enhances Liver Fibrosis Detection.
Med Sci Monit
; 22: 2878-85, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27526179
7.
[Clinical value of viral detection of liquid chip method in community-acquired pneumonia].
Zhonghua Yi Xue Za Zhi
; 95(4): 264-8, 2015 Jan 27.
Artículo
en Zh
| MEDLINE | ID: mdl-25877241
8.
[Analysis of diagnosis and treatment towards CHB patients complicated with fatty liver with complete virological response while biochemical suboptimal response].
Zhonghua Gan Zang Bing Za Zhi
; 23(5): 333-8, 2015 May.
Artículo
en Zh
| MEDLINE | ID: mdl-26192237
9.
[Correlation between liver hardness testing results obtained by FibroTouch and FibroScan and liver pathological stage].
Zhonghua Gan Zang Bing Za Zhi
; 22(6): 425-9, 2014 Jun.
Artículo
en Zh
| MEDLINE | ID: mdl-25203705
10.
Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis.
J Biol Chem
; 287(38): 32069-77, 2012 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22815486
11.
Aspartate Reduces Liver Inflammation and Fibrosis by Suppressing the NLRP3 Inflammasome Pathway via Upregulating NS3TP1 Expression.
J Pers Med
; 13(3)2023 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36983568
12.
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis.
Hepatol Int
; 17(6): 1350-1358, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37597121
13.
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Clin Mol Hepatol
; 29(3): 747-762, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37165622
14.
Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.
Front Cell Infect Microbiol
; 13: 1151899, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396307
15.
An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir.
J Clin Transl Hepatol
; 11(2): 304-313, 2023 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36643032
16.
Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT.
Clin Res Hepatol Gastroenterol
; 45(2): 101463, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32571749
17.
HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
J Gastroenterol
; 56(9): 856-867, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34292372
18.
Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
Hepatol Int
; 15(1): 82-92, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33460002
19.
Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks.
Int J Infect Dis
; 99: 171-178, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32721532
20.
Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study.
Infect Drug Resist
; 12: 745-757, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31015765